Who are Telmisartan, Ramipril's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/telmisartan-ramipril.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Telmisartan, Ramipril — Competitive Intelligence Brief

Telmisartan, Ramipril (Telmisartan, Ramipril) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin II receptor blocker + ACE inhibitor combination. Area: Cardiovascular.

phase 3 Angiotensin II receptor blocker + ACE inhibitor combination AT1 receptor (telmisartan); Angiotensin-converting enzyme (ramipril) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Telmisartan, Ramipril (Telmisartan, Ramipril) — Post Graduate Institute of Medical Education and Research, Chandigarh. This combination blocks angiotensin II signaling through two complementary pathways: telmisartan blocks the angiotensin II type 1 receptor, while ramipril inhibits ACE to prevent angiotensin II formation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Telmisartan, Ramipril TARGET	Telmisartan, Ramipril	Post Graduate Institute of Medical Education and Research, Chandigarh	phase 3	Angiotensin II receptor blocker + ACE inhibitor combination	AT1 receptor (telmisartan); Angiotensin-converting enzyme (ramipril)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiotensin II receptor blocker + ACE inhibitor combination class)

Post Graduate Institute of Medical Education and Research, Chandigarh · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Telmisartan, Ramipril — Competitive Intelligence Brief. https://druglandscape.com/ci/telmisartan-ramipril. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab